Clinical trial
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic…
NCT00449150 · AEterna Zentaris, Industry · Terminated
Key facts
| NCT number | NCT00449150 |
|---|---|
| Title | Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH) |
| Official title | Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment |
| Lead sponsor | AEterna Zentaris, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hypertrophy |
| Intervention type | Drug |
| Interventions | Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo |
| Enrollment | 667 |
| Start date | Mar 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Mar 19, 2007 |
| Last update posted | Aug 3, 2018 |
| Countries | Bulgaria, Canada, Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: